Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for autoimmune and rare diseases, today ...

Ocugen, Inc. (“Ocugen”) (NASDAQ: OCGN) today announced the pricing of $115 million aggregate principal amount of 6.75% Convertible Senior Notes due 2034 (the “notes”) in a private offering (the ...

Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced its intention to offer, subject to market and other conditions, $400 million aggregate principal amount of convertible senior notes due 2032 ...

(“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced its intention to offer, subject to market conditions and other ...

Knight-Swift Transportation Holdings Inc. (NYSE:KNX) (the “Company” or “Knight-Swift”), one of North America’s largest and most diversified freight transportation companies, announced today the ...

ProPetro Holding (NYSE:PUMP) shares fell 6% Monday after the company announced plans to offer $500 million in convertible senior notes due 2031 in a private place ...

MILL VALLEY, Calif.--(BUSINESS WIRE)--Redwood Trust, Inc. (NYSE: RWT; “Redwood” or the “Company”) today announced that it plans to offer, subject to market and other conditions, $50 million aggregate ...

ProPetro Holding Corp. (NYSE: PUMP) (together with its subsidiaries, “ProPetro” or the “Company”) today announced the pricing of its previously announced private offering of $600 million aggregate ...

ProPetro has priced a $600 million private offering of 0.00% convertible senior notes due 2031, up from an initial $500 million plan. Proceeds will fund capped call transactions to limit dilution and ...

Vancouver, British Columbia--(Newsfile Corp. - December 3, 2025) - First Majestic Silver Corp. (NYSE: AG) (TSX: AG) (FSE: FMV) ("First Majestic" or the "Company") announced today that it has priced ...

MINNEAPOLIS, July 28, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC) (the “Company”), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today ...

Repurchasing approximately $300 million principal amount of existing convertible senior notes and removing approximately 5.2 million underlying shares as well as approximately $51.4 million of ...